425: Core Scientific to Merge with CoreWeave in All-Stock Deal

Core Scientific's Board unanimously recommends stockholders vote for the all-stock merger with CoreWeave, citing significant pro forma benefits and de-risked execution.

Summary

• Core Scientific's Board of Directors unanimously recommends that stockholders vote FOR the proposed all-stock merger with CoreWeave, Inc.
• Core Scientific stockholders will receive 0.1235 newly-issued shares of CoreWeave Class A common stock for each share of Core Scientific common stock held.
• This exchange ratio reflects an approximately 71% premium to the 10-day Volume Weighted Average Price (VWAP) exchange ratio as of June 25, 2025, prior to media reports regarding a transaction.
• Core Scientific stockholders will receive an 8.9% ownership stake in the combined AI platform.
• The transaction is expected to close in Q4 2025, subject to approval by a majority of Core Scientific's outstanding common shares.
• The HSR waiting period for the transaction expired on August 25, 2025.
• CoreWeave is Core Scientific's primary colocation customer, projected to constitute approximately 95% of Core Scientific's colocation revenue and approximately 76% of its total projected revenue by 2026E.
• The majority of Core Scientific's current forward-looking value, approximately 72% of its Standalone Plan Discounted Cash Flow (DCF) value, is based on CoreWeave contracts.

Sentiment

Score: 9

Explanation: The filing presents a highly positive outlook on the merger, emphasizing significant premiums, de-risking of Core Scientific's business, substantial cost savings, and strong growth potential in the AI infrastructure market for the combined entity. The board's unanimous recommendation and successful negotiation of a higher exchange ratio further reinforce this positive sentiment.

Positives

• Provides Core Scientific stockholders with a significant upfront premium of approximately 71% to the 10-day VWAP exchange ratio as of June 25, 2025.
• Core Scientific stockholders gain an 8.9% ownership in a leading AI platform with strong momentum and potential for incremental price appreciation via multiple expansion.
• Eliminates Core Scientific's standalone execution risk on timely delivery of currently leased data centers and projected future leasing, as well as its ~$7.3 billion financing need.
• The combined company is expected to achieve over $500 million in fully ramped, annual run rate cost savings by the end of 2027E, including lease overhead elimination.
• Accelerates and de-risks the path to scale for both companies, with the majority of Core Scientific's asset base already reserved by CoreWeave.
• Verticalization creates a differentiated leading large-cap AI infrastructure player, strengthening the pro forma company's end-to-end AI technology stack.
• The transaction strengthens CoreWeave's capital position by converting a cash contract to an equity position and accelerates growth.
• The combined entity will benefit from greater financial flexibility and control over a critical power footprint and optionality for future power capacity.
• Core Scientific's Board successfully negotiated an approximately 34% increase in the exchange ratio from CoreWeave's initial offer.

Negatives

• CoreWeave indicated it was unwilling to pursue a fixed value deal (with or without a collar) or include cash in its proposal.
• Core Scientific stockholders will experience dilution from CoreWeave's issuance of additional shares in connection with the proposed transaction.
• The transaction involves an all-stock consideration, meaning Core Scientific stockholders will be subject to CoreWeave's stock performance.
• Potential for litigation relating to the proposed transaction could be instituted against Core Scientific, CoreWeave, or their respective directors and officers.
• Management's time and attention will be diverted to transaction-related issues during the pendency of the merger.

Risks

• The completion of the proposed transaction on anticipated terms or at all, including obtaining regulatory approvals and Core Scientific stockholder approval.
• Unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, and future prospects may differ from expectations.
• The possibility that any of the anticipated benefits of the proposed transaction will not be realized or will not be realized within the expected time period.
• The ability of Core Scientific and CoreWeave to integrate their businesses successfully and to achieve anticipated synergies and value creation.
• Potential litigation relating to the proposed transaction that could be instituted against Core Scientific, CoreWeave, or their respective directors and officers.
• Disruptions from the proposed transaction could harm Core Scientific's or CoreWeave's business, including current plans and operations, and divert management's time.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed transaction.
• Core Scientific's standalone plan required approximately $7.3 billion of total capital expenditures over eight years, with over 75% ($5.7 billion) in the first four years, which would be difficult to procure.
• The standalone plan included the risk of raising substantial debt capital, which would likely be very expensive or potentially unfeasible without contracted revenue.
• Core Scientific's current sub-scale business profile with single customer risk in its standalone plan.
• Pipeline CapEx buildout is significantly more expensive than contracted CapEx (approximately 7.9x higher per MW) and much of that CapEx would require pre-funding in advance of contracts.

Future Outlook

The combined Core Scientific and CoreWeave entity is positioned to capture a greater share of the ~$400 billion AI infrastructure market by 2028E. The transaction is expected to accelerate and de-risk the path to scale for both companies, enhance core profitability, and generate over $500 million in annual run rate cost savings by the end of 2027. CoreWeave's growth projections and current revenue backlog of over $55 billion (4x from 2024) suggest significant future momentum, with analysts maintaining confident price targets.

Management Comments

• The Core Scientific Board of Directors unanimously determined that the proposed transaction with CoreWeave represents the best available alternative for all Core Scientific stockholders and recommends all stockholders vote FOR the transaction.
• CoreWeave indicated it was unwilling to pursue a fixed value deal (with or without a collar) or include cash in its proposal, as such terms would not be acceptable to its Board.
• We believe that our best-of-breed software and infrastructure solution makes us optimally suited to capture these bleeding-edge training workloads.
• We believe that the mix of hardware across generations will ensure that we are optimally situated to capture all workload types, both inference and training.
• CoreWeave has since reaffirmed publicly on October 7th that its bid is best and final.

Industry Context

The merger positions the combined entity to capitalize on the rapidly expanding AI infrastructure market, projected to reach ~$400 billion by 2028. CoreWeave has recently secured significant deals with major players like OpenAI (up to $6.5 billion expansion) and Meta ($14.2 billion AI infrastructure deal), demonstrating strong demand for high-performance computing and AI-specific cloud services. This vertical integration of data center ownership and AI infrastructure services is a strategic move to enhance control over critical power footprints and optimize delivery timelines in a competitive and high-growth sector.

Comparison to Industry Standards

• CoreWeave currently trades at a significant discount to publicly traded comparable pureplay and diversified cloud companies (e.g., Alphabet Inc., Amazon.com, Inc., International Business Machines Corporation, Microsoft Corporation, Nebius Group N.V., Oracle Corporation) despite meaningfully higher growth projections.
• CoreWeave's projected revenue growth for 2026E is 129.8% and 46.7% for 2027E, significantly higher than the consensus median for selected public cloud companies (12.8% for 2026E, 12.9% for 2027E).
• CoreWeave's projected EBITDA growth for 2026E is 154.2% and 50.3% for 2027E, also substantially higher than the consensus median for selected public cloud companies (16.2% for 2026E, 20.7% for 2027E).
• The transaction's 71% premium to the 10-day VWAP unaffected exchange ratio places it within the top decile of all-stock exchange ratio transactions since 2004, indicating a highly attractive offer compared to historical benchmarks.

Legal Proceedings

• Potential litigation relating to the proposed transaction that could be instituted against Core Scientific, CoreWeave, or their respective directors and officers.

Related Party Transactions

• CoreWeave is Core Scientific's main colocation customer, projected to represent approximately 95% of Core Scientific's colocation revenue and approximately 76% of total projected revenue by 2026E.
• CoreWeave agreements constitute the majority (approximately 72%) of Core Scientific's standalone plan DCF value.
• CoreWeave and Core Scientific share a unique CapEx funding arrangement for contracted colocation, where CoreWeave funds up to $1.5 million per MW of data center build-out costs.

Stakeholder Impact

• Shareholders (Core Scientific): Receive a significant premium and ownership in a high-growth AI company, de-risking their investment from Core Scientific's standalone execution challenges and financing needs.
• Shareholders (CoreWeave): Benefit from vertical integration, accelerated scale, cost savings, and enhanced market position in AI infrastructure.
• Employees: Potential for streamlined business operations and integration, but also potential for redundancies in certain areas due to cost savings.
• Customers: The combined entity aims to provide a more robust and integrated AI infrastructure solution, potentially benefiting customers with enhanced services and delivery timelines.
• Creditors: The pro forma company is expected to have greater financial flexibility and a reduced overall cost of capital, potentially improving creditworthiness.

Next Steps

• Core Scientific stockholders are scheduled to hold a Special Meeting on October 30, 2025, to consider and vote upon the proposal to adopt the Agreement and Plan of Merger.
• The transaction is expected to close in Q4 2025, subject to stockholder approval.
• Integration of Core Scientific and CoreWeave businesses to achieve anticipated synergies and value creation.
• The combined company will pursue infrastructure financing strategies for committed capital expenditures.

Key Dates

Recommendation

The proposed all-stock merger offers Core Scientific stockholders a substantial premium (71% to 10-day VWAP) and an 8.9% ownership stake in CoreWeave, a rapidly growing AI infrastructure leader. This transaction significantly de-risks Core Scientific's future by eliminating its ~$7.3 billion capital expenditure requirement and associated financing challenges. The combined entity is poised for strong growth in the ~$400 billion AI market, with projected annual cost savings exceeding $500 million and CoreWeave's impressive revenue backlog and analyst price targets. The strategic vertical integration and enhanced financial flexibility create a compelling long-term value proposition, making it a strong buy for investors seeking exposure to the high-growth AI sector.

Keywords

Core Scientific, CoreWeave, Merger, Acquisition, All-stock transaction, AI infrastructure, Data center, Colocation, SEC filing, Corporate governance, Stockholder vote, Premium, Synergies, Risk management, Bitcoin mining